Evozyne
Chicago, US · Founded 2020 · 55 employees on LinkedIn · 7 known investors
Evozyne is an AI-native biotech that designs de novo therapeutic proteins using EvoGen, a machine learning engine, and EvoLab, a high-throughput experimental facility that synthesizes and tests candidate proteins. It focuses on immunology, advancing a pipeline of engineered proteins such as IgG proteases, next-generation cytokines, and respiratory disease candidates toward clinical evaluation.
Founders & leadership
AT
Aris TheologisExecutive
DP
Darien ParhadExecutive
PJ
Patrick J. MorrisExecutive
RR
Rama RanganathanNamed on SEC filing
Board
JS
Jeffrey S. AroninBoard director
AG
Antonio GraciasinBoard directorFounder, Chief Executive Officer & Chief Investment Officer at Valor Equity Partners
Investors · 7
OrbiMedNew York · $1M – $75M
Paragon Biosciences LLCChicago
Fidelity InvestmentsreportedBoston
NVenturesreportedSanta Clara
NVIDIAreportedSanta Clara
Valor Equity PartnersreportedChicagovia Antonio Gracias · board
Also in the syndicate · 1
Valor Equity Partner
Reported raises · per SEC filings
Form D private placements$144.4M disclosed across 3 rounds · 2020–2023
▶$81MraisedSep 2023 · 29 investors · BiotechnologyRule 506(b)
▶$81MraisedSep 2023 · 29 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Antonio GraciasDirector
- Jeffrey S. AroninExecutive Officer, Director
- Aris TheologisExecutive Officer
- Darien ParhadExecutive Officer
- Jude M. SullivanExecutive Officer
- Aleina LeeExecutive Officer
- Rama RanganathanExecutive Officer, Director
- Patrick J. MorrisExecutive Officer, Director
- Mike GamsonExecutive Officer, Director
- Matthew RizzoDirector
- Arjun RallapalliExecutive Officer
- Offering amount
- $100M
- Amount sold
- $81M
- Sales commissions
- $2M
- Placement agents
- Paragon Health Capital, LLC
- First sale
- Sep 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$54.2MraisedApr 2021 · 12 investors · BiotechnologyRule 506(b)
▶$54.2MraisedApr 2021 · 12 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aris TheologisExecutive Officer, Director
- Rama RanganathanExecutive Officer, Director
- Darien ParhadExecutive Officer
- Patrick J. MorrisExecutive Officer, Director
- Jeffrey S. AroninDirector
- Antonio GraciasDirector
- Offering amount
- $59.2M
- Amount sold
- $54.2M
- Sales commissions
- $1.6M
- Placement agents
- Paragon Health Capital
- First sale
- Apr 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$9.2MraisedMay 2020 · 2 investors · BiotechnologyRule 506(b)
▶$9.2MraisedMay 2020 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Aris TheologisExecutive Officer, Director
- Rama RanganathanExecutive Officer, Director
- Darien ParhadExecutive Officer
- Jeffrey S. AroninExecutive Officer, Director
- Antonio GraciasDirector
- Patrick J MorrisExecutive Officer, Director
- Offering amount
- $9.2M
- Amount sold
- $9.2M
- First sale
- Apr 2020
- Incorporated
- Limited Liability Company, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Evozyne do?
- Evozyne is an AI-native biotech that designs de novo therapeutic proteins using EvoGen, a machine learning engine, and EvoLab, a high-throughput experimental facility that synthesizes and tests candidate proteins. It focuses on immunology, advancing a pipeline of engineered proteins such as IgG proteases, next-generation cytokines, and respiratory disease candidates toward clinical evaluation.
- Who are Evozyne's investors?
- Evozyne's investors include OrbiMed, Paragon Biosciences LLC, Fidelity Investments, NVentures, NVIDIA, Valor Equity Partners.
- How much funding has Evozyne raised?
- Evozyne has disclosed $144.4M raised across 3 rounds.
- Where is Evozyne headquartered?
- Evozyne is headquartered in Chicago, US.